BIOCERES CROP SOLUTIONS CORP (BIOX) Stock Fundamental Analysis
NASDAQ:BIOX - KYG1117K1141 - Common Stock
2.7 USD
-0.11 (-3.91%)
We assign a fundamental rating of 3 out of 10 to BIOX. BIOX was compared to 84 industry peers in the Chemicals industry. BIOX may be in some trouble as it scores bad on both profitability and health. BIOX has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
BIOX had negative earnings in the past year.
BIOX had a positive operating cash flow in the past year.
In multiple years BIOX reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: BIOX reported negative operating cash flow in multiple years.
1.2 Ratios
BIOX's Return On Assets of -1.13% is on the low side compared to the rest of the industry. BIOX is outperformed by 61.90% of its industry peers.
The Return On Equity of BIOX (-2.94%) is comparable to the rest of the industry.
Looking at the Return On Invested Capital, with a value of 2.92%, BIOX is doing worse than 60.71% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for BIOX is in line with the industry average of 6.43%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.13% | ||
| ROE | -2.94% | ||
| ROIC | 2.92% |
ROA(3y)0.43%
ROA(5y)0.14%
ROE(3y)0.56%
ROE(5y)-0.23%
ROIC(3y)6.06%
ROIC(5y)8.13%
1.3 Margins
The Operating Margin of BIOX (5.69%) is worse than 60.71% of its industry peers.
In the last couple of years the Operating Margin of BIOX has declined.
BIOX's Gross Margin of 39.83% is amongst the best of the industry. BIOX outperforms 83.33% of its industry peers.
BIOX's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.69% | ||
| PM (TTM) | N/A | ||
| GM | 39.83% |
OM growth 3Y-17.81%
OM growth 5Y-13.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-2.6%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIOX is destroying value.
BIOX has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, BIOX has more shares outstanding
The debt/assets ratio for BIOX is higher compared to a year ago.
2.2 Solvency
The Debt to FCF ratio of BIOX is 9.52, which is on the high side as it means it would take BIOX, 9.52 years of fcf income to pay off all of its debts.
BIOX's Debt to FCF ratio of 9.52 is fine compared to the rest of the industry. BIOX outperforms 66.67% of its industry peers.
A Debt/Equity ratio of 0.28 indicates that BIOX is not too dependend on debt financing.
BIOX's Debt to Equity ratio of 0.28 is fine compared to the rest of the industry. BIOX outperforms 78.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 9.52 | ||
| Altman-Z | N/A |
ROIC/WACC0.33
WACC8.8%
2.3 Liquidity
A Current Ratio of 1.02 indicates that BIOX should not have too much problems paying its short term obligations.
BIOX has a worse Current ratio (1.02) than 90.48% of its industry peers.
A Quick Ratio of 0.74 indicates that BIOX may have some problems paying its short term obligations.
BIOX has a worse Quick ratio (0.74) than 84.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
The earnings per share for BIOX have decreased strongly by -551.72% in the last year.
BIOX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.69%.
The Revenue has been growing by 23.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-551.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.29%
Revenue 1Y (TTM)-13.69%
Revenue growth 3Y31.01%
Revenue growth 5Y23.73%
Sales Q2Q%-27.86%
3.2 Future
BIOX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 69.95% yearly.
Based on estimates for the next years, BIOX will show a small growth in Revenue. The Revenue will grow by 4.00% on average per year.
EPS Next Y-212.37%
EPS Next 2Y88.26%
EPS Next 3Y92.09%
EPS Next 5Y69.95%
Revenue Next Year-21.79%
Revenue Next 2Y-8.39%
Revenue Next 3Y-0.58%
Revenue Next 5Y4%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
BIOX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 12.91, BIOX is valued correctly.
Based on the Price/Forward Earnings ratio, BIOX is valued a bit cheaper than 61.90% of the companies in the same industry.
BIOX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.67, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.91 |
4.2 Price Multiples
BIOX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. BIOX is cheaper than 67.86% of the companies in the same industry.
BIOX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BIOX is cheaper than 96.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.9 | ||
| EV/EBITDA | 8.95 |
4.3 Compensation for Growth
A more expensive valuation may be justified as BIOX's earnings are expected to grow with 92.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y88.26%
EPS Next 3Y92.09%
5. Dividend
5.1 Amount
BIOX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:BIOX (8/27/2025, 11:20:01 AM)
2.7
-0.11 (-3.91%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)
Earnings (Next)
Inst Owners32.39%
Inst Owner Change-1.27%
Ins Owners1.33%
Ins Owner ChangeN/A
Market Cap169.32M
Analysts84
Price Target7.52 (178.52%)
Short Float %1.24%
Short Ratio3.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.45%
Min EPS beat(2)-89.82%
Max EPS beat(2)86.93%
EPS beat(4)1
Avg EPS beat(4)-297.85%
Min EPS beat(4)-1076.47%
Max EPS beat(4)86.93%
EPS beat(8)1
Avg EPS beat(8)-217.21%
EPS beat(12)2
Avg EPS beat(12)-43.03%
EPS beat(16)3
Avg EPS beat(16)-46.14%
Revenue beat(2)0
Avg Revenue beat(2)-13.11%
Min Revenue beat(2)-19.15%
Max Revenue beat(2)-7.07%
Revenue beat(4)0
Avg Revenue beat(4)-13.33%
Min Revenue beat(4)-19.15%
Max Revenue beat(4)-7.07%
Revenue beat(8)1
Avg Revenue beat(8)-8.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.28%
Revenue beat(16)8
Avg Revenue beat(16)9.32%
PT rev (1m)0%
PT rev (3m)-3.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)50%
EPS NY rev (1m)0%
EPS NY rev (3m)39.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 12.91 | ||
| P/S | 0.44 | ||
| P/FCF | 5.9 | ||
| P/OCF | 3.59 | ||
| P/B | 0.55 | ||
| P/tB | 11.7 | ||
| EV/EBITDA | 8.95 |
EPS(TTM)-0.13
EYN/A
EPS(NY)0.21
Fwd EY7.74%
FCF(TTM)0.46
FCFY16.96%
OCF(TTM)0.75
OCFY27.84%
SpS6.11
BVpS4.92
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.13% | ||
| ROE | -2.94% | ||
| ROCE | 4.68% | ||
| ROIC | 2.92% | ||
| ROICexc | 3.19% | ||
| ROICexgc | 10.26% | ||
| OM | 5.69% | ||
| PM (TTM) | N/A | ||
| GM | 39.83% | ||
| FCFM | 7.49% |
ROA(3y)0.43%
ROA(5y)0.14%
ROE(3y)0.56%
ROE(5y)-0.23%
ROIC(3y)6.06%
ROIC(5y)8.13%
ROICexc(3y)6.87%
ROICexc(5y)10.39%
ROICexgc(3y)15.77%
ROICexgc(5y)22.76%
ROCE(3y)9.78%
ROCE(5y)13.22%
ROICexcg growth 3Y-15.22%
ROICexcg growth 5Y-15.76%
ROICexc growth 3Y-21.1%
ROICexc growth 5Y-17.96%
OM growth 3Y-17.81%
OM growth 5Y-13.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.98%
GM growth 5Y-2.6%
F-Score4
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 9.52 | ||
| Debt/EBITDA | 1.89 | ||
| Cap/Depr | 77.16% | ||
| Cap/Sales | 4.81% | ||
| Interest Coverage | 0.88 | ||
| Cash Conversion | 103.14% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | N/A |
F-Score4
WACC8.8%
ROIC/WACC0.33
Cap/Depr(3y)107.09%
Cap/Depr(5y)127.69%
Cap/Sales(3y)4.36%
Cap/Sales(5y)4.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-551.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.29%
EPS Next Y-212.37%
EPS Next 2Y88.26%
EPS Next 3Y92.09%
EPS Next 5Y69.95%
Revenue 1Y (TTM)-13.69%
Revenue growth 3Y31.01%
Revenue growth 5Y23.73%
Sales Q2Q%-27.86%
Revenue Next Year-21.79%
Revenue Next 2Y-8.39%
Revenue Next 3Y-0.58%
Revenue Next 5Y4%
EBIT growth 1Y-42.48%
EBIT growth 3Y7.68%
EBIT growth 5Y7%
EBIT Next Year-15.56%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y332.69%
FCF growth 3YN/A
FCF growth 5Y-6.35%
OCF growth 1Y734.34%
OCF growth 3YN/A
OCF growth 5Y7.02%